Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

812 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Study rationale and design of OPTIMISE, a randomised controlled trial on the effect of benchmarking on quality of care in type 2 diabetes mellitus.
Nobels F, Debacker N, Brotons C, Elisaf M, Hermans MP, Michel G, Muls E; OPTIMISE (OPtimal Type 2 dIabetes Management Including benchmarking and Standard trEatment) International Steering Committee. Nobels F, et al. Among authors: elisaf m. Cardiovasc Diabetol. 2011 Sep 22;10:82. doi: 10.1186/1475-2840-10-82. Cardiovasc Diabetol. 2011. PMID: 21939502 Free PMC article. Clinical Trial.
Optimal type 2 diabetes mellitus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries.
Hermans MP, Brotons C, Elisaf M, Michel G, Muls E, Nobels F; (for the OPTIMISE (OPtimal Type 2 dIabetes Management Including benchmarking and Standard trEatment) International Steering Committee). Hermans MP, et al. Among authors: elisaf m. Eur J Prev Cardiol. 2013 Dec;20(6):1095-105. doi: 10.1177/2047487312449414. Epub 2012 May 17. Eur J Prev Cardiol. 2013. PMID: 22605788 Clinical Trial.
Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe.
Ferrieres J, De Ferrari GM, Hermans MP, Elisaf M, Toth PP, Horack M, Brudi P, Lautsch D, Bash LD, Baxter CA, Ashton V, Ambegaonkar B, Gitt AK. Ferrieres J, et al. Among authors: elisaf m. Eur J Prev Cardiol. 2018 Dec;25(18):1966-1976. doi: 10.1177/2047487318806359. Epub 2018 Oct 18. Eur J Prev Cardiol. 2018. PMID: 30335504
Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women.
Athyros VG, Ganotakis E, Kolovou GD, Nicolaou V, Achimastos A, Bilianou E, Alexandrides T, Karagiannis A, Paletas K, Liberopoulos EN, Tziomalos K, Petridis D, Kakafika A, Elisaf MS, Mikhailidis DP; Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative. Athyros VG, et al. Curr Vasc Pharmacol. 2011 Nov;9(6):647-57. doi: 10.2174/157016111797484080. Curr Vasc Pharmacol. 2011. PMID: 21476961 Clinical Trial.
Real-World Adequacy of Glycaemic Control in Treatment-Naïve Greek Patients with Type 2 Diabetes Mellitus Initiating Treatment with Metformin Monotherapy at the Maximum Tolerated Dose: The Reload Study.
Tsimihodimos V, Bargiota A, Pagkalos EM, Manes C, Papas A, Karamousouli E, Voss B, Elisaf MS. Tsimihodimos V, et al. Among authors: elisaf ms. Exp Clin Endocrinol Diabetes. 2020 Apr;128(4):224-230. doi: 10.1055/a-0824-6607. Epub 2019 Jan 22. Exp Clin Endocrinol Diabetes. 2020. PMID: 30669167
812 results